Literature DB >> 12729668

5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.

Hiroo Koyama1, Julia K Boueres, Wei Han, Edward J Metzger, Jeffrey P Bergman, Dominick F Gratale, Daniel J Miller, Richard L Tolman, Karen L MacNaul, Joel P Berger, Thomas W Doebber, Kwan Leung, David E Moller, James V Heck, Soumya P Sahoo.   

Abstract

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12729668     DOI： 10.1016/s0960-894x(03)00257-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  3 in total

1.  Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.

Authors:  Alex D Drilon; Sanjay Popat; Gauri Bhuchar; David R D'Adamo; Mary Louise Keohan; Cyril Fisher; Cristina R Antonescu; Samuel Singer; Murray F Brennan; Ian Judson; Robert G Maki
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

2.  Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance.

Authors:  Dennis C Mynarcik; Margaret A McNurlan; Mark M Melendez; James A Vosswinkel; Marie C Gelato
Journal:  Patholog Res Int       Date:  2011-04-12

Review 3.  An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes.

Authors:  Garima Bansal; Punniyakoti Veeraveedu Thanikachalam; Rahul K Maurya; Pooja Chawla; Srinivasan Ramamurthy
Journal:  J Adv Res       Date:  2020-01-22       Impact factor: 10.479
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.